20 November, 2020
Davis Polk advised Antengene Corporation Limited in connection with its initial public offering and listing on the Hong Kong Stock Exchange and an international offering in reliance on Rule 144A and Regulation S. The gross proceeds from the offering amounted to approximately HK$2.79 billion (US$357 million) prior to any exercise of the over-allotment option.
Antengene is a clinical-stage Asia-Pacific biopharmaceutical company focused on innovative oncology medicines, distinguishing itself through its strong R&D capabilities and strategic approach to developing novel oncology therapies. Antengene’s vision is to treat patients beyond borders and transform their lives by discovering, developing and commercializing global first-in-class, only-in-class and/or best-in-class therapies.
The Davis Polk corporate team included partners James C. Lin and Yang Chu, counsel Xuelin (Steve) Wang, associates Kai Sun, Tonny Yu and Jessica Ng, and registered foreign lawyer Jennifer (Yujia) Jiang. Counsel Alon Gurfinkel and associate Veronica Davis provided tax advice. Members of the Davis Polk team are based in the Hong Kong and London offices.
The announcement above is not offer for sale of securities in the United States. The securities referred to herein (the "Securities") have not been registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and may not be sold in the United States absent registration or an exemption from registration under the Securities Act. The issuer of the Securities does not intend to register any part of the offering in the United States or to conduct a public offering of the Securities in the United States.
